KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Q3 2025 value amounting to $8.2 million.

  • Aurinia Pharmaceuticals' Cost of Revenue rose 3549.3% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 472.39%. This contributed to the annual value of $28.2 million for FY2024, which is 9966.07% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Cost of Revenue of $8.2 million as of Q3 2025, which was up 3549.3% from $7.1 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Cost of Revenue ranged from a high of $8.9 million in Q2 2024 and a low of $48000.0 during Q1 2021
  • For the 5-year period, Aurinia Pharmaceuticals' Cost of Revenue averaged around $3.8 million, with its median value being $2.4 million (2022).
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 174133.02% in 2024, then plummeted by 2013.69% in 2025.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Cost of Revenue stood at $481000.0 in 2021, then soared by 183.16% to $1.4 million in 2022, then surged by 296.11% to $5.4 million in 2023, then increased by 2.91% to $5.6 million in 2024, then soared by 47.28% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, $7.1 million for Q2 2025, and $8.6 million during Q1 2025.